ISRN Vascular Medicine
Volume 2011 (2011), Article ID 912820, 9 pages
Aspirin in Neurology
1Instituto Nacional de Neurología y Neurocirugía Manuel Velasco Suárez, Insurgentes Sur 3877, Colonia la Fama, 14269 México, DF, Mexico
2Hospital Angeles Pedregal-Hospital Angeles México, Camino a Santa Teresa 1055, Col. Héroes de Padierna, 10700 México, DF, Mexico
Received 23 September 2011; Accepted 25 October 2011
Academic Editors: J. Jolkkonen, V. Larrue, and P. Tyrrell
Copyright © 2011 Yolanda Aburto-Murrieta et al. This is an open access article distributed under the Creative Commons Attribution License, which permits unrestricted use, distribution, and reproduction in any medium, provided the original work is properly cited.
Aspirin is widely used for the prevention of recurrent stroke in patients with transient ischaemic attack (TIA) of arterial origin, because it is effective and inexpensive. Clopidogrel and the combination of aspirin and extended-release dipyridamole are more effective than aspirin, but are also much more expensive. No other antithrombotic regimens provide significant advantages over aspirin, although cilostazol and the novel platelet protease-activated receptor-1 antagonist, SCH 530348, are currently being evaluated. Numerous trials have examined the efficacy of antiplatelet drugs, primarily aspirin for prevention of vascular events in patients with a prior TIA or stroke. Although many were small and inconclusive, the Antiplatelet Trialists’ Collaboration (ATC) individual patient data meta-analysis reported that among more than 23000 patients (from 21 randomized controlled trials), antiplatelet therapy (usually aspirin) compared with placebo or untreated control continued for a mean of 29 months was associated with a 22% reduction in the odds of recurrent ischemic stroke, myocardial infarction (MI), or vascular death (17.8% versus 21.4%, ).